Nanobiotix announced on November 13, 2025 that it has advanced its Curadigm Nanoprimer platform, a lipid‑based nanoparticle system that temporarily occupies liver clearance pathways to improve the bioavailability of intravenously administered therapeutics. The company filed four new patent applications to protect the platform and its potential applications across multiple therapeutic areas, underscoring a robust intellectual‑property strategy for this early‑stage technology.
During the 2025 Partnership Opportunities in Drug Delivery (PODD) conference held October 27‑28, 2025, Nanobiotix presented in‑vivo preclinical data showing that the Nanoprimer can enhance the delivery of nucleic‑acid and peptide‑based vaccines. The data suggest the platform could unlock new treatment modalities for oncology and infectious disease while also reducing liver toxicity, a major limitation of many IV drugs.
The Curadigm platform represents a strategic diversification beyond Nanobiotix’s flagship NBTXR3 radio‑enhancer. By leveraging its physics‑based expertise and existing manufacturing capabilities, the company aims to create a new growth engine. Matthieu Germain, Head of the Curadigm platform, noted that “extrahepatic delivery is a persistent barrier that has prevented potentially game‑changing therapies from improving outcomes for patients in need,” highlighting the platform’s potential to address a critical unmet need.
The filing of four new patents protects the core technology and its applications across a broad range of indications, reinforcing the company’s early‑stage IP moat and positioning it for future collaborations and product development.
Financially, Nanobiotix’s half‑year 2025 revenue rose to €26.6 million from €9.3 million in the same period of 2024, while cash and cash equivalents stood at €28.8 million as of June 30, 2025. The strong cash position provides runway to pursue the internal pipeline and external partnerships for the Nanoprimer platform.
Market reaction to the announcement was tempered by mixed analyst sentiment and valuation concerns. Investors weighed the platform’s potential against the company’s current unprofitable status and the broader biotech market volatility, leading to a cautious response to the news.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.